Wuxi Rex Medical Robot Co., Ltd. has completed a strategic Pre-A financing round worth tens of millions of yuan. The round was led by BGI Songhe, with participation from existing investor Meian Innovation. The proceeds will be used to accelerate R&D iteration and global commercial rollout for both its serious medical brand, Rex Bionics, and its consumer medical brand, Free Future. Leveraging self-balancing exoskeleton robotics and placing brain science at its core, the company has pioneered a new approach to neurological function reconstruction for patients with severe neurological injuries. It is also advancing brain-computer interface and neuromodulation technologies to build a closed-loop active rehabilitation system. BGI Songhe noted that Rex fills a gap in its brain science investment portfolio by serving as the physical carrier that translates neural intention into real movement. The firm plans to foster synergies between Rex and projects across its ecosystem, support the company's dual-track development, and help connect the full value chain.
